‹ Back

FDA's New Quality Management System Regulation: What Medical Device Manufacturers Need to Know

February 2026 | CAHIR Solutions

 

The FDA's Quality Management System Regulation (QMSR) officially took effect on February 2, 2026, marking the most significant update to medical device quality requirements in nearly three decades. This regulation replaces the traditional Quality System Regulation (21 CFR Part 820) and incorporates by reference ISO 13485:2016, aligning U.S. requirements with international standards used by regulatory authorities worldwide.

 

 

 

 

What Changed Under QMSR

The QMSR harmonizes FDA's quality framework with ISO 13485:2016, the international standard specific for medical device quality management systems. This alignment reduces regulatory duplication for manufacturers operating in multiple markets and modernizes the compliance landscape. The regulation applies to all finished device manufacturers who intend to commercially distribute medical devices in the United States, including those authorized through 510(k), PMA, HDE, and de novo pathways.

 

Key additions to the regulation include:

• Risk management requirements: ISO 13485:2016 now mandates formalized risk-based approaches throughout the device lifecycle

• Enhanced supplier controls: Manufacturers must apply ongoing, risk-informed assessments of supplier ability and performance

• Design and development clarity: Requirements align with international expectations while maintaining FDA-specific provisions where necessary

 

New Inspection Approach and Enforcement

On February 2, 2026, the FDA discontinued its longstanding Quality System Inspection Technique (QSIT) and began using the updated Inspection of Medical Device Manufacturers Compliance Program 7382.850. The new inspection approach aligns with ISO 13485:2016 principles and emphasizes risk-based assessment of quality management activities. FDA investigators are now expected to evaluate whether quality management activities are commensurate with the level of risk posed by the device.

 

The agency has also formalized procedures for remote regulatory assessments (RRAs), which may be conducted in lieu of or in advance of traditional on-site inspections.

Implications for Key Stakeholders

 

For Medical Device Manufacturers

Manufacturers face increased responsibility to clearly define processes, terminology, and risk-based decision-making rationale. While the QMSR provides greater flexibility in how quality systems are structured, that flexibility requires documented justification for quality decisions. Companies must ensure their quality management systems fully meet ISO 13485:2016 requirements while maintaining compliance with FDA-specific provisions under the FD&C Act.

 

For PMA and HDE submissions, manufacturers must provide documentation demonstrating QMSR compliance, as failure to meet these requirements can result in denial of marketing applications. The FDA has issued guidance on QMS documentation expectations for these pathways, though specific guidance for 510(k) and de novo submissions is still pending.

For Global Manufacturers

 

Foreign manufacturers benefit from harmonization with international standards, streamlining compliance efforts across markets. Companies already certified to ISO 13485:2016 will find alignment with U.S. requirements, though they must ensure compliance with FDA's additional clarifications and FD&C Act provisions.

 

For Supply Chain Partners

Component suppliers and contract manufacturers face heightened scrutiny under the QMSR's enhanced supplier control requirements. Manufacturers must conduct ongoing, risk-informed assessments of supplier performance, increasing accountability throughout the supply chain.

 

 

How CAHIR Solutions Can Help

Navigating the QMSR transition requires strategic planning, risk-based documentation, and deep regulatory expertise. CAHIR Solutions has 15+ years of foundation in helping healthcare and MedTech organizations navigate complex regulatory requirements, clinical validation, and compliance frameworks.

 

Our team provides:

• Strategic regulatory assessments: We evaluate your current quality management system against QMSR and ISO 13485:2016 requirements, identifying gaps and compliance risks

• Risk-based documentation support: Our experts help develop the documented rationale and risk assessments FDA inspectors now expect under the new inspection approach

• Data-driven compliance solutions: Leveraging our expertise in data science and analytics, we help you build measurable, auditable quality management processes that demonstrate compliance and drive continuous improvement

• Transition planning and implementation: We guide manufacturers through QMSR adoption, from supplier control enhancements to updated design and development procedures

 

CAHIR Solutions combines regulatory expertise with data-driven insights to help you turn QMSR compliance from a regulatory burden into a competitive advantage. Our comprehensive program evaluation and analytic solutions ensure accountability, generate efficiency and cost savings, and support long-term sustainability in today's evolving regulatory landscape.

Ready to ensure your quality management system meets QMSR requirements? Contact CAHIR Solutions today to learn how our regulatory experts can help your organization achieve seamless compliance and operational excellence.